Skip to main content
Rapid Reactions Logo

Longer-Term Follow-Up of Amivantamab + Lazertinib vs Osimertinib From the MARIPOSA Study

In the final video of this Rapid Reactions series, Beth Sandy, MSN, CRNP, FAPO, discusses data that continue to favor first-line amivantamab plus lazertinib over osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer after a median of 31 months of follow-up.

Zongertinib, a Novel HER2-Specific Tyrosine Kinase Inhibitor for HER2-Positive Solid Tumors with Brain Metastases

In this video, Beth Sandy, MSN, CRNP, FAPO, discusses data showing that zongertinib demonstrated manageable safety and promising efficacy in patients with HER2 aberration-positive solid tumors, including those with baseline brain metastases.

HARMONi-2: Phase 3 Study of Ivonescimab vs Pembrolizumab in 1L Treatment for Patients with PD-L1-Positive Advanced NSCLC

In this video, Beth Sandy, MSN, CRNP, FAPO, discusses ivonescimab, a bispecific antibody targeting PD-1 and VEGF that produced a tolerable safety profile and clinically significant improvement in efficacy compared with pembrolizumab.

Targeting HER2-Mutated NSCLC With Zongertinib

Zongertinib, a HER2 TKI, demonstrated clinically meaningful activity and tolerability in patients with NSCLC with and without brain metastases harboring a HER2 mutation.

Updated Data From ASCO of Beamion LUNG-1, a Phase 1a/1b Trial of Zongertinib in Patients With HER2 Aberration-Positive Solid Tumors

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses updated data from the phase 1a/1b trial of zongertinib in patients with HER2 aberration-positive solid tumors. In this video, she reports data from phase 1b, the ongoing dose expansion phase, which includes patients with HER2 mutation–positive NSCLC and focuses on nursing considerations for managing adverse events.

Ongoing Phase 3 Randomized Trial, Beamion LUNG-2, of Zongertinib Versus Standard of Care in Patients With Advanced NSCLC Harboring HER2 TKD Mutations

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses the trial design of Beamion LUNG-2, a randomized phase 3 trial of zongertinib versus standard of care in patients with locally advanced or metastatic NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. She discusses the role of nurses in clinical trials, including providing essential monitoring and support to patients during their trial participation.

Data From ASCO 2024: Exposure-Response Analysis of Trastuzumab Deruxtecan to Inform Dosing in Patients With HER2-Mutated NSCLC

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses results from an exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with HER2-mutated NSCLC. In her recap, she highlights the importance of education around dose adjustments to manage patient expectations.

Final Results of DESTINY-Lung02 from ASCO 2024: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC

Final results from the randomized phase 2 trial of trastuzumab deruxtecan in patients with HER2-mutant NSCLC were reported at ASCO 2024 and summarized in this video by Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP. She recaps the efficacy and safety data while highlighting the importance of nurses in assessing and managing adverse events associated with these medications.